An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy-Reference-Cited by-同舟云学术

An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy

Published:2021-06-04 Issue:2 Volume:63 Page:259-267
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Mease Ronnie C.,Kang Choong Mo,Kumar Vivek,Banerjee Sangeeta Ray,Minn Il,Brummet Mary,Gabrielson Kathleen L.,Feng Yutian,Park Andrew,Kiess Ana P.,Sgouros George,Vaidyanathan Ganesan,Zalutsky Michael R.,Pomper Martin G.

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference44 articles.

1. Meeting report from the Prostate Cancer Foundation PSMA Theranostics State of the Science meeting;Miyahira;Prostate.,2020

2. Jones W Griffiths K Barata PC Paller CJ. PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy. Cancers (Basel). 2020;12:1367.

3. The role of theranostics in prostate cancer;O’Dwyer;Semin Radiat Oncol.,2021

4. Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy

5. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma;Frontiers in Oncology;2024-09-10

2. Editorial: Theranostics as a driving force in nuclear medicine;Frontiers in Oncology;2024-09-06

3. PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranostics;Nuclear Medicine and Biology;2024-07

4. A third generation PSMA-targeted agent [211At]YF2: Synthesis and in vivo evaluation;Nuclear Medicine and Biology;2024-07

5. Alpha and Beta Radiation for Theragnostics;PET Clinics;2024-07